Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

1CE7

MISTLETOE LECTIN I FROM VISCUM ALBUM

Summary for 1CE7
Entry DOI10.2210/pdb1ce7/pdb
DescriptorPROTEIN (RIBOSOME-INACTIVATING PROTEIN TYPE II), 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total)
Functional Keywordsribosome-inactivating protein type ii, ribosome
Biological sourceViscum album (European mistletoe)
More
Total number of polymer chains2
Total formula weight53473.56
Authors
Krauspenhaar, R.,Eschenburg, S.,Perbandt, M.,Kornilov, V.,Konareva, N.,Mikailova, I.,Stoeva, S.,Wacker, R.,Maier, T.,Singh, T.P.,Mikhailov, A.,Voelter, W.,Betzel, C. (deposition date: 1999-03-18, release date: 2000-03-20, Last modification date: 2023-08-09)
Primary citationKrauspenhaar, R.,Eschenburg, S.,Perbandt, M.,Kornilov, V.,Konareva, N.,Mikailova, I.,Stoeva, S.,Wacker, R.,Maier, T.,Singh, T.P.,Mikhailov, A.,Voelter, W.,Betzel, C.
Crystal structure of mistletoe lectin I from Viscum album.
Biochem.Biophys.Res.Commun., 257:418-424, 1999
Cited by
PubMed Abstract: The crystal structure of the ribosome-inactivating protein (RIP) mistletoe lectin I (ML-I) from Viscum album has been solved by molecular replacement techniques. The structure has been refined to a crystallographic R-factor of 24.5% using X-ray diffraction data to 2.8 A resolution. The heterodimeric 63-kDa protein consists of a toxic A subunit which exhibits RNA-glycosidase activity and a galactose-specific lectin B subunit. The overall protein fold is similar to that of ricin from Ricinus communis; however, unlike ricin, ML-I is already medically applied as a component of a commercially available misteltoe extract with immunostimulating potency and for the treatment of human cancer. The three-dimensional structure reported here revealed structural details of this pharmaceutically important protein. The comparison to the structure of ricin gives more insights into the functional mechanism of this protein, provides structural details for further protein engineering studies, and may lead to the development of more effective therapeutic RIPs.
PubMed: 10198229
DOI: 10.1006/bbrc.1999.0470
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.7 Å)
Structure validation

226707

數據於2024-10-30公開中

PDB statisticsPDBj update infoContact PDBjnumon